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Abstract
Backround: Advancements in immunosuppressive therapy have significantly improved patient and
graft survival following renal transplantation. This is paralleled by an increasing occurrence of
posttransplantation malignancy.
Case presentation: We report on a patient who presented with a history reminding of colon
cancer seven years after receiving a kidney transplant. Initial diagnostic imaging seemed to confirm
this diagnosis showing a constricting colonic lesion. To our surprise, colonoscopy findings were
unremarkable. Review of the imaging studies revealed that the tumor-like picture was caused by
the renal graft impressing the intestine. The following search for malignancy in other locations
resulted in the diagnosis of glioblastoma multiforme of which the patient died several weeks later.
Conclusion: Follow-up of renal transplant patients must include screening tests directed at tumor
detection. Imaging studies and other tests in this patient group should be interpreted by physicians
who are familiar with transplant related peculiarities.
Backround
Kidney transplantation is the treatment of choice for
appropriate patients with chronic renal failure. With
advancements in immunosuppressive therapy patient and
graft survival have significantly improved over the last
decades. This achievement of long-term organ acceptance,
however, coincides with an increased occurrence of post-
transplantation malignancy [1]. We will present a renal
transplant patient who was referred to us because of sus-
pected colon cancer.
Case presentation
A 66 year old male patient who had received a renal trans-
plant seven years earlier because of IgA nephropathy in his
native kidneys was referred to us by his nephrologist. His
graft had functioned well and his creatinine was stable at
130 µmol/l with an immunosuppressive regimen of
cyclosporine, azathioprine, and prednisolone that he had
received since his surgery. Over the past 6 months he
reported a 6 kg weight loss and increasing nausea. He had
also noted loose, darkish stools several times daily and
significant night sweats but no fever. He denied having
travelled outside of Germany in the past year. His neph-
rologists had noted small contracted native kidneys, an
unremarkable graft and normal remaining abdominal
structures in an ultrasound study. A gastroscopy, chest x-
ray and urological evaluation were unremarkable. All tests
conducted for infectious diseases were negative. The hae-
moglobin and hematocrit, liver enzymes, thyroid hor-
mone levels and serum proteins were normal. His
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4 mg/dl. His nephrologists, who suspected an intestinal
malignancy in this transplanted patient, referred him to
our service for colonoscopy and further evaluation.
The physical examination, including neurological exami-
nation was unremarkable. The blood pressure was 120/80
mmHg, the heart rate was 70/min. Our laboratory studies
confirmed the ambulatory results. The cyclosporine level
was in the therapeutic range. Serologic testing showed no
signs of acute infection with adenovirus, Epstein-Barr
Virus, Chlamydia pneumoniae, or Borrelia. PCR for CMV-
DNA was negative. A colonoscopy was performed but was
only successful to the level of the proximal sigmoid colon.
The examination was terminated because of pain and def-
inite resistance the gastroenterologist could not pass.
Other than scattered diverticuli, the mucosa was normal.
We next scheduled a radiocontrast to visualize the colon.
In this study a constricting lesion was encountered in the
cecum which the radiologist identified as a typical sign of
colon cancer (figure 1). A computerized tomography was
performed which showed a concentric wall thickening of
the ascending colon about 3 cm above the cecum, which
according to the radiologist, was consistent with the diag-
nosis of colon cancer (figure 2, panel a). All other abdom-
inal organs were unremarkable otherwise or consistent
with the earlier ultrasound examination. Before surgery
another attempt at colonoscopy was scheduled. To our
surprise, the second colonoscopy, performed with addi-
tional analgesia and sedation, revealed, a completely nor-
mal examination including the cecum. To address the
obvious discrepancy between this result and the prior
radiological findings we consulted another radiologist.
She noticed that the radiocontrast study was performed
with the patient lying prone (figure 1). Moreover, she
pointed out the proximity of the ascending colon to the
renal graft as shown in the computerized tomography,
performed in the supine position (figure 2, panel b). She
suggested that with the patient in this position, the graft
could squash the colon in such a fashion that the instilled
radiocontrast agent would produce a constricting tumor-
like image. With these new insights we were forced to start
from scratch and to look for a different diagnosis explain-
ing the patient's symptoms. During his hospital stay we
had observed that the patient, although unremarkable in
the general neurological examination, appeared slow and
sometimes inappropriate. In a mini-mental examination
we found a significant reduction in cognitive function.
The neurologist also found no localizing signs, but addi-
tional psychomotor testing verified rapidly progressive
early dementia. A magnetic resonance imaging study of
the brain was performed, revealing an infiltrating, destruc-
tive, multilocular lesion in the frontal lobe, (figure 3). The
process was consistent with a malignant tumor and less
suggestive of an infectious process. The patient was trans-
ferred to the neurosurgical section where a brain biopsy
secured the diagnosis of glioblastoma multiforme. Radia-
tion therapy was started but over the course of the next
few days the patient's general status deteriorated rapidly
and he became progressively more somnolent. Radiation
had to be stopped and 6 weeks after initial admission the
patient died.
Conclusion
A significantly increased incidence of malignancy is well
documented in renal transplant recipients if compared to
the general population [1]. With improvements in immu-
nosuppressive regimens that prolong patient and graft
survival, neoplastic disease has developed into a frequent
long-term complication in kidney recipients. One study
found that 40 percent of renal graft recipients had cancer
after 20 years of immunosuppression [2]. Many types of
posttransplant cancers display a more malignant course
than the same type of cancer in non-transplant patients.
This aggressive behaviour of posttransplant malignancy
contributes to the associated mortality causing 26 percent
of deaths in patients surviving transplantation for at least
10 years [3].
One of the contributing factors to posttransplant cancer is
the immunosuppressive therapy [1]. The association of
immunosuppressive therapy and cancer development is
also known from non-transplant patients but the precise
role of immunosuppressive drugs in carcinogenesis is not
fully understood. There is experimental evidence that the
inhibition of immunological responses, especially after
giving anti-T cell antibodies, increases cancer susceptibil-
ity by interfering with the host's anti-cancer surveillance
system [1,4]. Accordingly, the amount of immunosup-
pression would be directly correlated to the risk of cancer.
While this applies clinically to renal graft recipients on
high-dose versus low-dose cyclosporine [5] it has also
been demonstrated that cyclosporine is still carcinogenic
in mice without an immune system [6]. This is partly
ascribed to a TGF-beta dependent mechanism as cancer
progression could be inhibited by TGF-beta blockade [6].
Similar effects have been reported for tacrolimus which
also promoted cancer growth in immunodeficient mice
[7]. A direct carcinogenic potential has recently been high-
lighted for azathioprine which increases the risk of skin
cancer through higher UVA radiation sensitivity and sub-
sequent DNA mutations [8]. In contrast to these cancer
promoting side effects of calcineurin inhibitors and aza-
thioprine, inhibitors of target-of-rapamycin (TOR), such
as sirolimus and everolimus, seem to inhibit primary and
metastatic tumor growth [9,10]. TOR inhibitor treatment
was associated with reduced TGF-beta levels and with
attenuated VEGF signalling [9,10]. A recent multivariate
analysis including more than 30.000 kidney recipients
showed a three times higher incidence rate of posttrans-Page 2 of 6
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compared to patients on sirolimus or everolimus [11].
Another study followed 15 renal transplant patients with
Kaposi's sarcoma while they were switched from
cyclosporine to sirolimus [12]. Three months after the
switch all Kaposi's sarcoma lesions had disappeared while
Water-soluble contrast study performed after instillationFigure 1
Water-soluble contrast study performed after instillation. The patient is lying prone. The cecum appears filled with a space-
occupying lesion that the radiologist interpreted as highly suspicious of tumor.Page 3 of 6
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CT in the supine positionFigure 2
CT in the supine position. Panel A: The wall of the ascending colon was interpreted as 'thickened'. Panel B: CT at the level of 
the cecum showing the renal transplant kidney functioning well. The kidney is adjacent to the ascending colon and cecum.
BMC Nephrology 2006, 7:9 http://www.biomedcentral.com/1471-2369/7/9no graft rejection occurred and the serum creatinine
stayed stable [12]. These and other studies indicate that
TOR inhibitors have an equivalent immunosuppressive
potency but a reduced risk of malignancy.
Guided by our patient's history we agreed with the refer-
ring nephrologist and suspected post-transplant malig-
nancy. Considering the negative results of outpatient
gastroscopy, x-ray and ultrasound together with reported
Magnetic resonance imaging of the brain revealed a left frontal, invasive, multilocular, infiltrating processFigure 3
Magnetic resonance imaging of the brain revealed a left frontal, invasive, multilocular, infiltrating process.Page 5 of 6
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changes in bowel habits, we wrongly assumed the colon
as the most likely tumor location. This assumption
seemed to be confirmed by the misinterpreted radiologi-
cal findings. While the incidence of rectal cancer is
decreased in transplant patients, the risk of colon cancer is
significantly increased [13]. A general odds ratio hierarchy
of tumor risk in kidney transplanted patients shows in
decreasing order: Non-melanoma skin cancer, thyroid
and other endocrine tumors, oral cavity cancers, cervix
and vaginal cancers, non-Hodgkin lymphoma, renal, ure-
teral, and bladder cancer, colorectal cancer, lung cancer,
and brain tumors [14]. Our patient's final diagnosis was
glioblastoma multiforme, which together with other
brain tumors has an odds ratio of 2.5 in transplant
patients. Although we were not able to help our patient
this case illustrates several aspects:
1. Transplant patients need a regular history, physical
examination and screening tests directed at tumor detec-
tion (reviewed in reference 1).
2. The prevalence and the behaviour of specific types of
cancers in transplant recipients are significantly different
from the general population.
3. Post-transplant malignancy can only in part be
explained by immunosuppression itself.
4. Imaging studies in transplant patients should be inter-
preted by physicians familiar with transplant related pecu-
liarities.
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